Home/Products /trioxsalen-25mg-tablet

Trioxsalen 25mg Tablet PCD Pharma Franchise Delhi

Name: Trifoli 25 Tablet ( Trioxsalen (25mg) Tablet)
Brand: Trifoli 25 Tablet
Rating: 4.8 (150 reviews)

Trioxsalen 25mg Tablet Manufacturing Company Baddi

Trioxsalen 25mg Tablet Dermatology Franchise Pune

Trioxsalen 25mg Tablet Pharma Supplier Mumbai

Trioxsalen 25mg Tablet Export Company Chennai

Trioxsalen 25mg Tablet Franchise Opportunity Hyd

Therapeutic

ENDOCRINOLOGY and Hormonal range

Gastroenterology

General and OTC medicines

Gynecology and Fertility

Hepatology

Hypertension/ Blood Pressure

Nutraceuticals, Multivitamins and Multiminerals

Sedative or Antianxiety

Stimulant

Urology

Trioxsalen 25mg Tablet in PCD Pharma Franchise

Trioxsalen 25mg Tablet in Third Party Manufacturing

Trioxsalen 25mg Tablet from Best Pharma Exporter

Trioxsalen 25mg Tablet by Top Pharma Company in India

Trifoli 25 Tablet in Dermatology Medicine Franchise

Trifoli 25 Tablet

Composition : Trioxsalen (25mg) Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹171/-

Please Contact For Best Price

Trifoli 25 Tablet contains Trioxsalen, a psoralen derivative used in combination with ultraviolet A (UVA) light therapy to treat certain skin conditions. It works as a photosensitizing agent that, upon activation by UVA light, interacts with DNA in skin cells to regulate abnormal cell growth and pigmentation. The 25 mg strength is typically used as part of PUVA (Psoralen + UVA) therapy. Trioxsalen helps repigment skin in conditions such as vitiligo and reduces excessive cell proliferation in psoriasis. It is also used in some cases of eczema and cutaneous T-cell lymphoma under specialist supervision. Trifoli 25 enhances melanin production in the skin, aiding in the restoration of normal pigmentation when used appropriately with controlled UVA exposure.

About the Product

Common side effects include nausea, itching, mild redness, or dryness of the skin after UVA exposure. Some patients may experience headache or dizziness. Serious but rare adverse effects include blistering, severe phototoxic reactions, hyperpigmentation, premature skin aging, or an increased long-term risk of skin cancer if PUVA therapy is not carefully monitored. Eye sensitivity to light may also occur, requiring protective eyewear.

Trifoli 25 Tablet is indicated for the treatment of vitiligo, particularly for inducing repigmentation in depigmented patches, and for the management of psoriasis and other PUVA-responsive dermatoses. It may also be prescribed for certain cases of mycosis fungoides (cutaneous T-cell lymphoma).

Trifoli 25 Tablet should only be taken under dermatological supervision as part of a controlled PUVA therapy protocol. Patients must strictly follow the recommended UVA exposure schedule to avoid burns or phototoxic damage. Protective eyewear must be worn during and after treatment to prevent eye damage and cataract formation. It is contraindicated in pregnancy, breastfeeding, and in patients with a history of skin cancer, lupus, or photosensitivity disorders. Avoid sun exposure for at least 8 hours after taking the tablet unless under medical guidance, as it can cause severe burns. Regular monitoring by a healthcare professional is essential to ensure safe and effective therapy.

Store Trifoli 25 Tablet in a cool, dry place below 25–30°C, protected from light and moisture. Keep the medication in its original packaging and out of reach of children. Do not use after the expiry date printed on the strip.